Literature DB >> 713265

Pathology of analgesic nephropathy: Australian experience.

A Burry.   

Abstract

Analgesic nephropathy was first studied in Switzerland and Scandinavia, and most observers thought that papillary necrosis, a feature of the pathology, was the result of chronic interstitial nephritis, the other principal feature. From 1962, reports indicated a high incidence of analgesic nephropathy in Australia and suggested that papillary changes preceded cortical damage. Later, associated uroepithelial carcinoma was noted. Early papillary lesions consist of necrosis of elements around groups of collecting ducts. Necrosis extends upward through the medulla from the papilla and gradually intensifies to total papillary destruction. Fat and calcium accumulation and changes in matrix mucopolysaccharide are markers of papillary injury. Cortical atrophy is dependent upon collecting duct obstruction and is proportional to the degree of obstruction. Infection may complicate late pathologic changes. It is suggested that in the early stages the disease represents an injury to "concentrating columns" in the medulla.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 713265     DOI: 10.1038/ki.1978.5

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  4 in total

Review 1.  Analgesic nephropathy: a reassessment of the role of phenacetin and other analgesics.

Authors:  L F Prescott
Journal:  Drugs       Date:  1982 Jan-Feb       Impact factor: 9.546

2.  Intratubular calcium phosphate deposition in acute analgesic nephropathy in rabbits.

Authors:  H L Hennis; G R Hennigar; W B Greene; C W Hilton; M Spector
Journal:  Am J Pathol       Date:  1982-03       Impact factor: 4.307

Review 3.  Effects of non-narcotic analgesics on the kidney.

Authors:  P Kincaid-Smith
Journal:  Drugs       Date:  1986       Impact factor: 9.546

4.  Analgesic-associated nephropathy.

Authors:  A Schwarz
Journal:  Klin Wochenschr       Date:  1987-01-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.